HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH), effective September 15, 2025, covering over 51 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT). The CNSide® CSF Assay Platform supports rapid di ...

Core Insights - Plus Therapeutics, Inc. is set to launch its CNSide cerebrospinal fluid (CSF) assay platform and testing services in Texas by August 2025, focusing initially on NCI-Designated Cancer Centers and large private healthcare systems [2][9] - The CNSide assay is designed to diagnose and monitor leptomeningeal metastases (LM), a severe complication of advanced cancer, with a high sensitivity of 92% and specificity of 95% [6][7] - The company has conducted over 11,000 CNSide tests at more than 200 U.S. cancer institutions since 2020, demonstrating significant clinical utility and influencing treatment decisions in over 90% of cases [6][8] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, focusing on developing targeted radiotherapeutics for difficult-to-treat CNS cancers [9] - CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, develops proprietary laboratory tests to identify tumor cells that have metastasized to the CNS [8] - The CNSide CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA, improving patient management for those with LM [8] Market Context - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with median survival typically ranging from 2 to 6 months, indicating a critical need for effective diagnostic tools and therapies [7] - The current standard of care, CSF cytology, has suboptimal sensitivity, leading to missed or delayed diagnoses, which CNSide aims to address with its advanced testing capabilities [6][5]